Drugs / BIIB093
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03954041 | Oct 2019 → Jun 2023 | brain injury | Remedy Pharmaceuticals, Inc. | Terminated | Missed primary Stop: Business |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02864953 | Aug 2018 → Aug 2023 | brain edema, ischemic stroke | Remedy Pharmaceuticals, Inc. | Terminated | Missed primary Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-09-04 | Biogen | Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction biogen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB093 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02864953 ↗ |
| Route | Intravenous | “BIIB093 administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.” NCT02864953 ↗ |